Global Hereditary Angioedema Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

• In August 2018, Shire announced U.S Food and Drug Administration (FDA) approval for TAKHZYRO, as a preventive treatment for hereditary angioedema.

• In June 2017, CSL Behring received approval from U.S Food and Drug Administration (FDA) for HAEGARDA, a subcutaneous therapy used to prevent hereditary angioedema attacks in adolescent and adult patients.

The Global Hereditary Angioedema (HAE) Treatment Market has been segmented by drug class, application, route of administration, and distribution channel, each contributing to the growth and development of treatment options for this rare and potentially life-threatening condition. By drug class, the market is primarily divided into C-1 Esterase Inhibitors, Bradykinin Receptor Antagonists, and Kallikrein Inhibitors. C-1 Esterase Inhibitors are the most commonly used treatments for HAE, aimed at replacing or supplementing the deficient or dysfunctional C-1 esterase inhibitor in patients with HAE. Bradykinin Receptor Antagonists, such as icatibant, are utilized to block the effects of bradykinin, a key mediator of angioedema, thus preventing attacks. Kallikrein Inhibitors, which target the enzyme kallikrein involved in the production of bradykinin, represent a newer class of treatment options, providing further choices for managing the condition effectively.

By application, the market is divided into prophylaxis and treatment. Prophylactic treatments are aimed at preventing angioedema attacks, often administered regularly to patients with frequent episodes or severe forms of HAE, thereby reducing the burden of attacks. On the other hand, treatments during acute attacks focus on rapid intervention to relieve symptoms and minimize damage, particularly in emergency situations where swelling of the airway could be life-threatening. Both types of applications are crucial for managing the condition, though the emphasis on prophylaxis is increasing as the understanding of HAE improves, allowing patients to live more normal lives.

By route of administration, the market is segmented into intravenous (IV), subcutaneous injection, and oral formulations. IV administration is typically used in emergency situations, providing rapid onset of action. Subcutaneous injections offer a more convenient option for patients managing their condition at home, allowing for self-administration. Oral formulations are gaining attention due to their ease of use, particularly for long-term prophylaxis, providing patients with a less invasive and more comfortable alternative to injectables.

By distribution channel, the market is divided into hospital pharmacies, retail pharmacies, and others. Hospital pharmacies are the primary point of distribution for patients in acute settings, where prompt treatment is critical. Retail pharmacies provide accessibility to prescription treatments, offering patients the ability to fill prescriptions for regular prophylactic use. Other distribution channels, including online pharmacies and specialized healthcare providers, contribute to expanding access, especially for patients who may not have immediate access to traditional pharmacy services. This segmentation highlights the diverse treatment landscape for hereditary angioedema, driven by innovations in drug classes, administration routes, and the need for accessible distribution.

Global Hereditary Angioedema Treatment Segment Analysis

In this report, the Global Hereditary Angioedema Treatment Market has been segmented by Drug Class, Application, Route Of Administration, Distribution Channel and Geography.

Global Hereditary Angioedema Treatment Market, Segmentation by Drug Class

The Global Hereditary Angioedema Treatment Market has been segmented by Drug Class into C-1 Esterase Inhibitors, Bradykynin Receptor Antagonist, and Kallikrein Inhibitors.

The Global Hereditary Angioedema (HAE) Treatment Market has been segmented by drug class into C-1 Esterase Inhibitors, Bradykinin Receptor Antagonists, and Kallikrein Inhibitors, each playing a significant role in managing and treating HAE symptoms. C-1 Esterase Inhibitors are the most widely used and established treatment for HAE, primarily focusing on replacing or supplementing the deficient or dysfunctional C-1 esterase inhibitor in patients with HAE. These inhibitors are effective in preventing or controlling the frequency and severity of angioedema attacks, and they are often administered during acute episodes or as part of a long-term prophylactic treatment plan. Their well-established clinical efficacy and safety make them a mainstay in HAE management.

Bradykinin Receptor Antagonists, such as icatibant, work by blocking the bradykinin receptor, a key mediator involved in the swelling and inflammation associated with HAE attacks. By preventing bradykinin from binding to its receptor, these antagonists effectively reduce the severity and duration of angioedema attacks. Bradykinin receptor antagonists are typically used in the treatment of acute attacks, offering patients a rapid-acting therapeutic option with a relatively quick onset of action, making them valuable in emergency situations.

Kallikrein Inhibitors are a newer class of drugs targeting the kallikrein enzyme, which is responsible for the production of bradykinin, the molecule that triggers inflammation and fluid leakage in HAE patients. By inhibiting kallikrein, these treatments prevent the excessive production of bradykinin, thus reducing the frequency and severity of angioedema attacks. Kallikrein inhibitors represent an important innovation in HAE therapy, providing an additional treatment option for patients who may not respond to traditional therapies or those seeking alternative treatments.

These three drug classes—C-1 Esterase Inhibitors, Bradykinin Receptor Antagonists, and Kallikrein Inhibitors—comprise the core therapeutic strategies in the HAE treatment market, offering targeted and effective solutions to manage the condition, reduce symptoms, and improve the quality of life for affected individuals. As treatment options evolve, new formulations and approaches within these drug classes continue to expand the available therapeutic landscape for HAE patients.

Global Hereditary Angioedema Treatment Market, Segmentation by Application

The Global Hereditary Angioedema Treatment Market has been segmented by Application into Prophylaxis and Treatment.

Prophylactic treatments are often administered on a regular basis, aiming to reduce the frequency and intensity of attacks, providing patients with a better quality of life. These treatments are essential for patients with a history of recurrent swelling, particularly those who experience airway involvement, which can lead to life-threatening situations. Prophylaxis may include long-term use of C-1 esterase inhibitors, kallikrein inhibitors, or other drugs designed to stabilize patients and prevent acute episodes.

On the other hand, treatment involves addressing acute angioedema attacks when they occur. Treatment focuses on rapidly managing symptoms and reducing swelling to prevent complications, especially in cases where attacks affect critical areas like the throat or airway. Drugs like bradykinin receptor antagonists are often used in these situations, as they work quickly to block the bradykinin receptor and reduce swelling. The treatment approach also includes the use of C-1 esterase inhibitors and kallikrein inhibitors to counteract the underlying pathophysiology of HAE. While prophylaxis aims to prevent attacks, treatment focuses on immediate relief and emergency care when symptoms emerge.

Together, both prophylaxis and treatment segments are essential for managing HAE, with prophylactic therapies helping to reduce the overall burden of the disease and treatment interventions providing fast relief during acute episodes. The growing understanding of HAE and the development of more targeted and effective treatments have expanded options for both preventing and managing the disease, leading to improved outcomes for patients worldwide.

Global Hereditary Angioedema Treatment Market, Segmentation by Route Of Administration

The Global Hereditary Angioedema Treatment Market has been segmented by Route Of Administration into Intravenous, Subcutaneous Injection and Oral.

Intravenous (IV) treatments are typically administered in healthcare settings, such as hospitals or infusion centers, and are used for acute attacks or for patients with severe or frequent HAE episodes. IV administration allows for rapid delivery of medications directly into the bloodstream, ensuring immediate and effective symptom relief. Common therapies administered intravenously include C1 inhibitor concentrates, which help manage acute attacks by replacing the deficient protein in the body.

Subcutaneous Injection therapies offer a more convenient alternative to intravenous administration, allowing patients to self-administer the medication at home. Subcutaneous injections are increasingly popular in the HAE treatment market, particularly for patients seeking long-term disease management or those with less frequent swelling episodes. These injections typically include C1 inhibitor products or other targeted therapies that can be administered by the patient with ease, providing flexibility and reducing hospital visits.

Oral medications are also gaining traction in the market due to their convenience and ease of use. Oral therapies, such as small molecule inhibitors, are designed for both acute and preventive treatment of HAE episodes. They provide a non-invasive option for patients, allowing for more regular and consistent treatment regimens. The development of oral treatments represents a growing trend towards patient-centered care, offering increased comfort and improved quality of life for those living with hereditary angioedema. These different routes of administration ensure that patients have access to the most suitable treatment options for their needs, improving disease management and overall outcomes.

Global Hereditary Angioedema Treatment Market, Segmentation by Distribution Channel

The Global Hereditary Angioedema Treatment Market has been segmented by Distribution Channel into Hospital Pharmacies, Retail Pharmacies and Others.

The global hereditary angioedema (HAE) treatment market is characterized by a variety of distribution channels that ensure the accessibility and availability of medications to patients worldwide. One key distribution channel is hospitals, where patients receive comprehensive care and treatments for acute attacks and long-term management of HAE. Hospitals often serve as primary points of care, especially for patients experiencing severe symptoms requiring immediate medical intervention. These facilities are equipped with specialized healthcare professionals and necessary resources to administer advanced treatments, including intravenous therapies and novel biologics, ensuring optimal patient outcomes.

Another significant distribution channel is retail pharmacies, which provide easier and more convenient access to HAE treatments for many patients. Retail pharmacies are integral in dispensing oral medications, self-injectable therapies, and other prescribed treatments, making it simpler for patients to manage their condition at home. The presence of retail pharmacies in both urban and rural areas helps bridge the gap in healthcare accessibility, allowing patients to obtain their medications promptly and consistently. Additionally, pharmacists play a crucial role in educating patients about their treatments, potential side effects, and the importance of adherence to prescribed regimens.

The online pharmacy segment has seen substantial growth, particularly in the wake of the COVID-19 pandemic, which accelerated the shift towards digital health solutions. Online pharmacies offer a convenient and often cost-effective alternative for obtaining HAE medications, particularly for patients who may have difficulty accessing traditional brick-and-mortar pharmacies. These platforms provide the added benefit of discreet delivery services, comprehensive drug information, and sometimes telehealth consultations, enhancing patient convenience and adherence to treatment plans. The increasing acceptance of digital health services and improvements in logistical networks have made online pharmacies a vital component of the distribution landscape in the HAE treatment market.

Global Hereditary Angioedema Treatment Market, Segmentation by Geography

In this report, the Global Hereditary Angioedema Treatment Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.

Global Hereditary Angioedema Treatment Market Share (%), by Geographical Region, 2024

The global hereditary angioedema (HAE) treatment market exhibits significant regional variations, driven by differences in healthcare infrastructure, awareness levels, and economic factors. In North America, the market is notably robust, primarily due to advanced healthcare systems, high awareness among patients and healthcare providers, and the presence of key market players. The United States, in particular, accounts for a substantial share of the market, supported by favorable reimbursement policies and extensive research activities aimed at improving treatment options.

In Europe, the hereditary angioedema treatment market is also substantial, with countries such as Germany, France, and the United Kingdom leading the way. The European market benefits from well-established healthcare frameworks and strong regulatory support for rare disease treatments. Collaborative efforts among European nations for research and patient support initiatives further bolster the market. Additionally, the increasing adoption of advanced therapies and a growing focus on early diagnosis and management of HAE contribute to the market's expansion in this region.

The Asia-Pacific region is witnessing a gradual growth in the HAE treatment market, propelled by rising healthcare expenditures and improving healthcare access in countries like China, Japan, and India. While the market is still in its nascent stages compared to North America and Europe, increasing awareness campaigns and government initiatives aimed at enhancing healthcare infrastructure are driving growth. Furthermore, the growing presence of multinational pharmaceutical companies in the region and their efforts to tap into the unmet needs of HAE patients are expected to significantly boost the market in the coming years.

This report provides an in depth analysis of various factors that impact the dynamics of Global Hereditary Angioedema Treatment Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.

Drivers, Restraints and Opportunity Analysis

Key players in Global Hereditary Angioedema Treatment Market include:

• Shire plc (Takeda Pharmaceutical Company Limited)
• CSL Limited
• Pharming Group N.V
• Ionis Pharmaceuticals Inc
• BioCryst Pharmaceuticals Inc
• KalVista Pharmaceuticals Ltd
• Attune Pharmaceuticals

In this report, the profile of each market player provides following information:

• Company Overview and Product Portfolio
• Key Developments
• Financial Overview
• Strategies
• Company SWOT Analysis